ASCT Benefited Younger, Older Multiple Myeloma Patients Equally, Study Finds
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.
Myeloma
Alkeran-based 4-drug Combo Gives Excellent Outcomes in Myeloma Patients Undergoing Transplants
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…
Revlimid for Myeloma After Stem Cell Transplant Gets Nod from EMA Panel
The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…
Combo Therapy After Stem Cell Transplant Improves Survival in Myeloma Patients, Trial Finds
Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent…
Cellectar’s Patent for Anti-cancer Compounds Includes Potential Myeloma Therapy
Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR 125 in the treatment of…
Longer Dosing Interval of Zoledronic Acid Found Acceptable for Bone Metastasis
Patients with bone metastasis due to multiple myeloma, breast or prostate cancer, who received zoledronic acid every 12 weeks for two years, did not have increased risk of skeletal-related events…
Vickar Foundation Donates $2M for Oncology and Blood Disorders Research
The Kerry and Simone Vickar Family Foundation has committed $2 million to establish an endowed chair in their name at the Levine Cancer…
Dendritic Cell Immunotherapy Failed to Gain Upper Hand in Relapsed, Refractory Myeloma in Study
A new type of dendritic cell-based immunotherapy triggered an immune response in the majority of patients in a small Phase 1 trial (NCT02248402) of…
Targeting Genetic Alterations in Multiple Myeloma May Suppress Tumor Growth, Study Suggests
Changes in gene activity in the DNA of multiple myeloma cells can lead to the progression of the disease by shutting down the expression of…
Janssen and BMS to Test Darzalex, Opdivo Combo in Multiple Myeloma and Solid Tumors
Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL